Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
出版年份 2018 全文链接
标题
Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs
作者
关键词
-
出版物
JOURNAL OF LEUKOCYTE BIOLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2018-07-12
DOI
10.1002/jlb.5ri0218-084r
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study
- (2018) H. Nakagawa et al. BRITISH JOURNAL OF DERMATOLOGY
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
- (2018) Anna Sophia McKenney et al. JOURNAL OF CLINICAL INVESTIGATION
- Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases
- (2018) Michael L. Vazquez et al. JOURNAL OF MEDICINAL CHEMISTRY
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms
- (2017) Gabriela S. Hobbs et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Group 1 Innate Lymphoid Cell Lineage Identity Is Determined by a cis -Regulatory Element Marked by a Long Non-coding RNA
- (2017) Walter K. Mowel et al. IMMUNITY
- A Case Series on Patients on Tofacitinib in Combination With a Biologic
- (2017) Nashla S. Barroso et al. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
- Subset- and tissue-defined STAT5 thresholds control homeostasis and function of innate lymphoid cells
- (2017) Alejandro V. Villarino et al. JOURNAL OF EXPERIMENTAL MEDICINE
- STAT5B: A Differential Regulator of the Life and Death of CD4+Effector Memory T Cells
- (2017) Sonia S. Majri et al. JOURNAL OF IMMUNOLOGY
- Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy
- (2017) David T. Beattie et al. Journal of Inflammation-London
- Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans
- (2017) Atli Thorarensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin
- (2017) Peter Jones et al. JOURNAL OF MEDICINAL CHEMISTRY
- Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor
- (2017) Fiona Elwood et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis
- (2017) Edward C. Keystone et al. JOURNAL OF RHEUMATOLOGY
- Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure
- (2017) Lucy Y. Liu et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Janus kinase inhibitors in dermatology: A systematic review
- (2017) Rony Shreberk-Hassidim et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A phase 1 study of the Janus kinase 2 ( JAK2 ) V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia
- (2017) Srdan Verstovsek et al. LEUKEMIA RESEARCH
- Jak3 deficiency blocks innate lymphoid cell development
- (2017) M L Robinette et al. Mucosal Immunology
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors
- (2017) Dafna Gladman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial dysfunction induced by a SH2 domain-targeting STAT3 inhibitor leads to metabolic synthetic lethality in cancer cells
- (2017) Davide Genini et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study
- (2017) Satoshi Kubo et al. RHEUMATOLOGY
- Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study
- (2017) Kensuke Kume et al. RHEUMATOLOGY INTERNATIONAL
- Tofacitinib rapidly ameliorated polyarthropathy in a patient with systemic sclerosis
- (2017) T Komai et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Type I Interferon in Chronic Virus Infection and Cancer
- (2017) Laura M. Snell et al. TRENDS IN IMMUNOLOGY
- Responses to Cytokines and Interferons that Depend upon JAKs and STATs
- (2017) George R. Stark et al. Cold Spring Harbor Perspectives in Biology
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors
- (2017) Christina Gavegnano et al. PLoS Pathogens
- Genome-Wide Association Meta-Analysis Reveals Novel Juvenile Idiopathic Arthritis Susceptibility Loci
- (2017) Laura A. McIntosh et al. Arthritis & Rheumatology
- The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
- (2017) Richard Furie et al. Arthritis & Rheumatology
- Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
- (2017) Roy Fleischmann et al. Arthritis & Rheumatology
- Role of Type I and II Interferons in Colorectal Cancer and Melanoma
- (2017) Simone Di Franco et al. Frontiers in Immunology
- Efficacy of VX-509 (decernotinib) in combination with a disease-modifying antirheumatic drug in patients with rheumatoid arthritis: clinical and MRI findings
- (2016) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
- (2016) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial
- (2016) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling
- (2016) Andy J. Minn et al. CELL
- The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia
- (2016) Matthew D. Blunt et al. CLINICAL CANCER RESEARCH
- Mitochondrial STAT3: Powering up a potent factor
- (2016) Daniel J. Garama et al. CYTOKINE
- Emancipation from transcriptional latency: unphosphorylated STAT5 as guardian of hematopoietic differentiation
- (2016) Thomas Decker EMBO JOURNAL
- Phosphoproteomic Analyses of Interleukin 2 Signaling Reveal Integrated JAK Kinase-Dependent and -Independent Networks in CD8 + T Cells
- (2016) Sarah H. Ross et al. IMMUNITY
- Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173 -activating mutations in 3 children
- (2016) Marie-Louise Frémond et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Evolution of Cytokine Receptor Signaling
- (2016) Clifford Liongue et al. JOURNAL OF IMMUNOLOGY
- Essential biphasic role for JAK3 catalytic activity in IL-2 receptor signaling
- (2016) Geoffrey A Smith et al. Nature Chemical Biology
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
- (2016) Vibeke Strand et al. RHEUMATOLOGY
- Trisomy 21 consistently activates the interferon response
- (2016) Kelly D Sullivan et al. eLife
- Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
- (2016) Mark C. Genovese et al. Arthritis & Rheumatology
- A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy
- (2016) Joel M. Kremer et al. Arthritis & Rheumatology
- Molecular mechanisms of pruritus
- (2016) J. Meng et al. Current Research in Translational Medicine
- THU0174 Analysis of Non-melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Programme
- (2015) J. Curtis et al. ANNALS OF THE RHEUMATIC DISEASES
- OP0029 Baricitinib, An Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to TNF Inhibitors: Results of the Phase 3 RA-Beacon Study:
- (2015) M.C. Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- SAT0349 Patient-Reported Outcomes from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA) and an Inadequate Response to Tumor Necrosis Factor Inhibitors: Table 1
- (2015) J.S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
- (2015) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention
- (2015) John J. O'Shea et al. Annual Review of Medicine
- Gone fission: an asymptomaticSTAT2mutation elongates mitochondria and causes human disease following viral infection
- (2015) Asish Dasgupta et al. BRAIN
- The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
- (2015) S J Thomas et al. BRITISH JOURNAL OF CANCER
- Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
- (2015) R. Bissonnette et al. BRITISH JOURNAL OF DERMATOLOGY
- CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
- (2015) Sara C. Meyer et al. CANCER CELL
- Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia
- (2015) Shuo-Chieh Wu et al. CANCER CELL
- Phase I study of OPB-51602, an oral inhibitor of signal transducer and activator of transcription 3, in patients with relapsed/refractory hematological malignancies
- (2015) Michinori Ogura et al. CANCER SCIENCE
- Tofacitinib for the treatment of moderate-to-severe psoriasis
- (2015) Andrea Chiricozzi et al. Expert Review of Clinical Immunology
- Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain
- (2015) John S. Tokarski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
- (2015) R Zeiser et al. LEUKEMIA
- Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)
- (2015) Lara Brambilla et al. Molecular Oncology
- The selection and function of cell type-specific enhancers
- (2015) Sven Heinz et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Type I/II cytokines, JAKs and new strategies for treating autoimmune diseases
- (2015) Daniella M. Schwartz et al. Nature Reviews Rheumatology
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preliminary response to Janus kinase inhibition with baricitinib in chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperatures (CANDLE)
- (2015) G Montealegre et al. Pediatric Rheumatology
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer
- (2015) David Hong et al. Science Translational Medicine
- Super-enhancers: Asset management in immune cell genomes
- (2015) Steven Witte et al. TRENDS IN IMMUNOLOGY
- Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial
- (2015) Joel M Kremer et al. ARTHRITIS RESEARCH & THERAPY
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
- (2015) Roy M. Fleischmann et al. Arthritis & Rheumatology
- VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib
- (2015) Christina Charles-Schoeman et al. Arthritis & Rheumatology
- An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy
- (2015) Vijay U. Rao et al. Arthritis & Rheumatology
- Pharmacologic inhibition of JAK-STAT signaling promotes hair growth
- (2015) S. Harel et al. Science Advances
- The molecular regulation of Janus kinase (JAK) activation
- (2014) Jeffrey J. Babon et al. BIOCHEMICAL JOURNAL
- Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations
- (2014) J. D. Milner et al. BLOOD
- A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease
- (2014) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Selective JAK inhibitors in development for rheumatoid arthritis
- (2014) Peter Norman EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Intravenous golimumab in rheumatoid arthritis
- (2014) Marc D Cohen et al. Expert Review of Clinical Immunology
- Kinase inhibitors: The next generation of therapies in the treatment of rheumatoid arthritis
- (2014) Lindsey A. MacFarlane et al. International Journal of Rheumatic Diseases
- Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
- (2014) James D. Clark et al. JOURNAL OF MEDICINAL CHEMISTRY
- Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies
- (2014) J. Wollenhaupt et al. JOURNAL OF RHEUMATOLOGY
- Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease
- (2014) Sarah E Flanagan et al. NATURE GENETICS
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- (2014) Luzhou Xing et al. NATURE MEDICINE
- Toward a new STATe: The role of STATs in mitochondrial function
- (2014) Jeremy A. Meier et al. SEMINARS IN IMMUNOLOGY
- Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis
- (2014) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
- (2013) Joel Kremer et al. ANNALS OF INTERNAL MEDICINE
- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
- (2013) Mi-Jung Kim et al. CANCER LETTERS
- Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation–polyendocrinopathy–enteropathy–X-linked–like syndrome
- (2013) Gulbu Uzel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib
- (2013) Naoko Okiyama et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: A Cumulative Analysis of Up to 4.6 Years of Exposure
- (2013) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- STAT2 deficiency and susceptibility to viral illness in humans
- (2013) S. Hambleton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined Analysis of Genome-wide Association Studies for Crohn Disease and Psoriasis Identifies Seven Shared Susceptibility Loci
- (2012) David Ellinghaus et al. AMERICAN JOURNAL OF HUMAN GENETICS
- U.S. Food and Drug Administration Approval: Ruxolitinib for the Treatment of Patients with Intermediate and High-Risk Myelofibrosis
- (2012) A. Deisseroth et al. CLINICAL CANCER RESEARCH
- Janus Kinase Deregulation in Leukemia and Lymphoma
- (2012) Edwin Chen et al. IMMUNITY
- Inborn Errors of Human JAKs and STATs
- (2012) Jean-Laurent Casanova et al. IMMUNITY
- The JAK-STAT Pathway at Twenty
- (2012) George R. Stark et al. IMMUNITY
- Targeting IL-17 and TH17 cells in chronic inflammation
- (2012) Pierre Miossec et al. NATURE REVIEWS DRUG DISCOVERY
- SomaticSTAT3Mutations in Large Granular Lymphocytic Leukemia
- (2012) Hanna L.M. Koskela et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-in-Human Trial of a STAT3 Decoy Oligonucleotide in Head and Neck Tumors: Implications for Cancer Therapy
- (2012) Malabika Sen et al. Cancer Discovery
- Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen
- (2011) B. C. Betts et al. BLOOD
- FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma
- (2011) N. E. Elliott et al. BLOOD
- Dynamics and non-canonical aspects of JAK/STAT signalling
- (2011) Anne Mohr et al. EUROPEAN JOURNAL OF CELL BIOLOGY
- Receipt of Disease-Modifying Antirheumatic Drugs Among Patients With Rheumatoid Arthritis in Medicare Managed Care Plans
- (2011) Gabriela Schmajuk et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
- Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate
- (2011) Yoshiya Tanaka et al. ARTHRITIS CARE & RESEARCH
- Differentiation of Effector CD4 T Cell Populations
- (2010) Jinfang Zhu et al. Annual Review of Immunology
- Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
- (2010) Andre Franke et al. NATURE GENETICS
- Differential effects of STAT5 and PI3K/AKT signaling on effector and memory CD8 T-cell survival
- (2010) T. W. Hand et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CP-690550, a Janus Kinase Inhibitor, Suppresses CD4+ T-Cell–Mediated Acute Graft-Versus-Host Disease by Inhibiting the Interferon-γ Pathway
- (2010) Hyung-Bae Park et al. TRANSPLANTATION
- Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study inDe NovoKidney Allograft Recipients
- (2009) S. Busque et al. AMERICAN JOURNAL OF TRANSPLANTATION
- Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial
- (2009) J H Coombs et al. ANNALS OF THE RHEUMATIC DISEASES
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders
- (2009) Ana L. Basquiera et al. Hematology
- JAK mutations in high-risk childhood acute lymphoblastic leukemia
- (2009) C. G. Mullighan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- ITP three R's: regulation, routing, rituximab
- (2008) J. W. Semple BLOOD
- Mining for JAK–STAT mutations in cancer
- (2008) Stefan N. Constantinescu et al. TRENDS IN BIOCHEMICAL SCIENCES
- A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis
- (2008) Allison L Smitten et al. ARTHRITIS RESEARCH & THERAPY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started